This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nova Pharma Solutions Berhad Announces Interim Single-Tier Dividend for the Financial Year Ending 31 December 2023, Payable on 15 September 2023 CI
Nova Pharma Solutions' Profit, Revenue Rise in H1 MT
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nova Pharma Solutions Berhad Proposes Interim Single-Tier Dividend for the Financial Year Ending 31 December 2022 CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2022 CI
67,054,279 Ordinary Shares of Nova Pharma Solutions Berhad are subject to a Lock-Up Agreement Ending on 9-MAR-2022. CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Nova Pharma Solutions Berhad entered into an agreement to acquire remaining 49% stake in NOVA HITECH SOLUTIONS SDN. BHD from ACARA JUARA SDN BHD for MYR 0.05 million. CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Nova Pharma Solutions Berhad Appoints Mr. Ng Tik Hwa as Independent and Non Executive Director CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Nova Pharma Solutions Berhad Announces Single-Tier Interim Dividend for the Financial Year Ending 31 December 2019, Payment Date of 17 Jan. 2020 CI
Nova Pharma Solutions Berhad Approves Interim Single- Tier Dividend for the Financial Year Ending 31 December 2019 CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2019 CI
Nova Pharma Solutions Berhad Announces Final Single Tier Dividend for the Financial Year Ended 31 December 2018, Payable on 08 August 2019 CI
Nova Pharma Solutions Berhad Announces Incorporation of Nova Incorporation of Hitech Solutions Sdn Bhd CI
Nova Pharma Solutions Berhad Announces Joint Venture Cum Shareholders Agreement with Acara Juara Sdn Bhd CI
Nova Pharma Solutions Berhad Proposes Final Single Tier Dividend, Payable on 08 August 2019 CI
Nova Pharma Solutions Berhad Announces Resignation of Tan Hong Eng as Executive Director CI
67,030,228 Ordinary Shares of Nova Pharma Solutions Berhad are subject to a Lock-Up Agreement Ending on 9-MAR-2019. CI
NOVA PHARMA SOLUTIONS BERHAD Recommends Final Single-Tier Dividend for the Financial Year Ended December 31, 2018 CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2018 CI
Nova Pharma Solutions Berhad Announces Single-Tier Interim Dividend for the Year Ending 31 December 2018, Payable on 18 January 2019 CI
Chart Nova Pharma Solutions
More charts
Nova Pharma Solutions Berhad is a Malaysia-based company, which is engaged in the business of provision of technical documentation, validation, and project execution in the pharmaceutical and biological industries. It operates through four segments: Design, Post Design, engineering, procurement, construction, and commissioning (EPCC) and Other Support. The Design segment comprise conceptual designs which include user requirement specification, capacity analysis and process scheduling with detailed costing, list of deliverables, details specification of various equipment’s. The Post Design segment comprise tendering and procurement support as well as construction management of plant. The EPCC segment comprise of works and services pertaining to engineering, procurement, construction, and commissioning for advanced technology facilities. The Other Support segment comprise of services to assist customer in the manufacturing practice document review and gap analysis and assessment.
More about the company
  1. Stock Market
  2. Equities
  3. NPS Stock
  4. News Nova Pharma Solutions
  5. Nova Pharma Solutions' Profit, Revenue Rise in H1